Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13541
Title: Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495.
Austin Authors: Burrell, Louise M ;Farina, N K;Risvanis, John;Woollard, D;Casely, D;Johnston, Colin I
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
Issue Date: 1-Jul-1997
Publication information: Clinical Science 1997; 93(1): 43-50
Abstract: 1. Inhibition of neutral endopeptidase (NEP), the degradative enzyme for atrial natriuretic peptide, was studied in vitro and in vivo using a previously characterized NEP inhibitor radioligand, 125I-labelled RB104. 2. SCH 42354, the active di-acid of the ethylester prodrug, SCH 42495, caused a concentration-dependent displacement of 125I-labelled RB104 from rat renal NEP. The concentration of SCH 42354 that displaced 50% of radioligand bound to the enzyme NEP (IC50) was 3.3 +/- 0.1 nmol/l (mean +/- SEM). Enalaprilat, an angiotensin converting enzyme inhibitor, did not displace 125I-labelled RB104 in concentrations up to 10 mumol/l. 3. In adult normotensive Sprague-Dawley rats, oral SCH 42495 (3-300 mg/kg) caused significant inhibition of renal NEP (P < 0.001). SCH 42495 had no effect on renal or plasma angiotensin converting enzyme activity, but high-dose SCH 42495 (300 mg/kg) caused a significant increase in plasma renin activity (P < 0.01). 4. In a time course study, oral SCH 42495 (30 mg/kg) caused rapid (within 30 min) and significant inhibition of renal NEP for up to 48 h (P < 0.001). No changes in plasma atrial natriuretic peptide or plasma angiotensin converting enzyme activity were seen. 5. These data provide evidence that short-term administration of the NEP inhibitor SCH 42495 results in inhibition of renal NEP and does not inhibit the circulating or the tissue renin-angiotensin system. The NEP inhibitor radioligand 125I-labelled RB104, is a useful tool to study tissue NEP inhibition after administration of NEP inhibitors.
Gov't Doc #: 9279202
URI: http://ahro.austin.org.au/austinjspui/handle/1/13541
URL: https://pubmed.ncbi.nlm.nih.gov/9279202
Type: Journal Article
Subjects: Administration, Oral
Animals
Atrial Natriuretic Factor.metabolism
Binding, Competitive
Dose-Response Relationship, Drug
Female
Iodine Radioisotopes.diagnostic use
Iodobenzenes.administration & dosage.pharmacology
Kidney.drug effects.enzymology
Methionine.administration & dosage.analogs & derivatives.pharmacology
Neprilysin.antagonists & inhibitors
Peptidyl-Dipeptidase A.blood
Prodrugs.administration & dosage.pharmacology
Rats
Rats, Sprague-Dawley
Renin.blood
Time Factors
gamma-Aminobutyric Acid.administration & dosage.analogs & derivatives.pharmacology
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Nov 25, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.